Softwr

Healthcare · head to head

Annalise.ai vs Clue

Annalise.ai logo

Annalise.ai

Healthcare

Multi-finding chest X-ray and head CT triage AI with FDA clearance on named findings, not on the whole model

From
On request
Rated
-
Full reviewWebsite
Clue logo

Clue

Healthcare

Period and cycle tracking app owned by German company Biowink, positioned around science based tracking and a published stance against sharing data with law enforcement

From
Free
Rated
-
Full reviewWebsite

The short version

  • Only Clue has a free tier, so it costs nothing to try first.
  • Each has a real cost: Annalise.ai the United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.; Clue clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.
  • They diverge on capability: Annalise.ai covers Annalise Enterprise CXR, Clue covers Cycle and symptom tracking.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Annalise.ai and Clue actually diverge.

Attributes where Annalise.ai and Clue differ
AttributeAnnalise.aiClue
Starting priceOn requestFree
Pricing modelquoteFree with a Plus subscription
Free tierNoYes
PlatformsWeb, Cloud, On-premiseiOS, Android

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Annalise.ai

  • Annalise Enterprise CXR
  • Annalise Enterprise CTB
  • Triage and notification
  • Worklist reprioritisation
  • Localisation overlays
  • Confidence output
  • PACS-native deployment
  • On-premise or cloud inference

Only in Clue

  • Cycle and symptom tracking
  • Cycle insights and patterns
  • Research partnerships
  • EU-based data hosting
  • Fertility and conception mode
  • Perimenopause and other life stage tracking

What people use each for

The jobs each tool is most often brought in to do.

Annalise.ai

  • An emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnestnot Clue
  • A teleradiology provider covering many small hospitals that needs consistent triage before a human readsnot Clue
  • A screening programme in Europe where the broader CE marked decision support indication, rather than the narrow United States triage clearance, is what is being deployednot Clue
  • A radiology department building an AI governance programme that wants one vendor covering both chest radiograph and head CT rather than contracting two separate algorithm suppliersnot Clue

Clue

  • Someone specifically weighing data jurisdiction and legal exposure when choosing a period tracking app, given Clues EU basis and published stance on law enforcement requestsnot Annalise.ai
  • A user who wants cycle tracking positioned around scientific research partnerships rather than lifestyle or community contentnot Annalise.ai
  • A buyer comparing Clue directly against Flo on current published privacy policy language before choosing which app to trustnot Annalise.ai
  • Someone tracking perimenopause or other non-standard cycle stages that some period apps do not support wellnot Annalise.ai

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Annalise.ai

  • The United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.
  • Triage AI reprioritises a worklist but does not change clinical decisions on its own, so departments that do not redesign how urgent studies are picked up see no measurable improvement in time to treatment.
  • Published validation is largely reader study evidence on detection of individual findings; prospective evidence of shorter time to treatment in routine emergency care is thin.
  • The Annalise brand is being migrated under the Harrison.ai name for the critical care offering, which creates ambiguity in multi-year contracts about what product name is actually being supported.
  • A high finding count raises the alert burden, and departments report that low prevalence findings generate false positives that erode radiologist trust unless the alerting thresholds are tuned locally.

Clue

  • Clues stated policy on not sharing data with law enforcement without a valid legal process is the companys own published position and legal interpretation, not an independent guarantee, and it can still be compelled to comply with a legally binding request under EU or other applicable law.
  • Deeper cycle insights and predictions, the features most likely to justify tracking in the first place, are gated behind the Clue Plus subscription rather than fully free.
  • Being a smaller company than some competitors, Clue has less capital and legal resource to contest large-scale legal requests than a larger, better-funded rival might, despite its stated intent to do so.
  • Research partnerships using anonymised user data, while opt-in, still mean user-derived data can be used in ways beyond direct app functionality, and users should check current consent settings.
  • Cycle predictions rely on self-reported data and general population models, so accuracy for irregular cycles or specific medical conditions remains limited regardless of which app is used.

Pricing, plan by plan

Annalise.ai

On request
  • Annalise Enterprise$undefined/year
    • Priced per study analysed or as an annual volume subscription
    • CXR and CTB licensed separately
    • Cleared finding set differs by market, which changes what you are buying

Clue

Free
  • Clue Plus$9.99/month
    • Free tier covers core cycle tracking, logging and basic predictions
    • Clue Plus adds deeper cycle insights, extended predictions and personalised content
    • Annual Plus plans typically offered at a lower effective monthly rate

Which should you pick?

Choose Annalise.ai if

  • You need annalise enterprise cxr.
  • You work on Web, Cloud, On-premise.
  • You also want annalise enterprise ctb.
Annalise.ai review

Choose Clue if

  • You need cycle and symptom tracking.
  • You want to start without paying.
  • You work on iOS, Android.
  • You also want cycle insights and patterns.
Clue review

Questions people ask

Is Annalise.ai or Clue better?
Neither clearly leads. Annalise.ai starts at On request and Clue at Free, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Annalise.ai or Clue?
Clue has a free tier; the other does not. Paid plans start at On request for Annalise.ai and Free for Clue.
Does Annalise.ai or Clue run on more platforms?
Annalise.ai runs on Web, Cloud, On-premise. Clue runs on iOS, Android.
Can I use Clue for free?
Yes. Clue has a free tier, so you can try it without paying. Annalise.ai starts at On request.
What is Annalise.ai best used for?
Annalise.ai is most often used for an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest, a teleradiology provider covering many small hospitals that needs consistent triage before a human reads, a screening programme in europe where the broader ce marked decision support indication, rather than the narrow united states triage clearance, is what is being deployed, a radiology department building an ai governance programme that wants one vendor covering both chest radiograph and head ct rather than contracting two separate algorithm suppliers. Of those, an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest and a teleradiology provider covering many small hospitals that needs consistent triage before a human reads are not what Clue is typically brought in for.
What can Annalise.ai do that Clue cannot?
Annalise.ai covers Annalise Enterprise CXR, Annalise Enterprise CTB, Triage and notification, Worklist reprioritisation. Clue covers Cycle and symptom tracking, Cycle insights and patterns, Research partnerships, EU-based data hosting.

Answered from the vendors’ own pages

Annalise.ai: How many findings are FDA cleared?

Around ten across chest X-ray and head CT, for triage and notification only. The model reports far more findings than that; the rest are not cleared in the United States.

Clue: Does Clue share data with law enforcement?

Clue publishes a policy stating it does not share health data with law enforcement or public authorities without a legally binding request and states it will challenge requests it considers improper. This is the companys stated position; verify the current policy directly for specifics.

Annalise.ai: Is the European position different?

Yes. CE marking under the medical device regulation covers a broader decision support indication than the United States triage and notification clearances, so the same software is a different regulatory product depending on where you deploy it.

Clue: Why does Clue emphasise being an EU company?

Clue operates under EU GDPR data protection rules and states this legal basis makes it harder for authorities outside the EU, including US authorities, to compel data disclosure than for a company based in the US.

Annalise.ai: Does it diagnose?

No. In the United States it is a triage and notification device: it flags studies for earlier review, and the radiologist makes the diagnosis.

Clue: Is Clue free?

Core cycle tracking, logging and basic predictions are free. Deeper insights and extended predictions require Clue Plus.

Annalise.ai: Is Annalise.ai becoming Harrison.ai?

The critical care offering is now marketed under the Harrison.ai name. Ask the vendor to name the contracted product explicitly before signing a multi-year deal.

Share

Related pages

More on Annalise.ai

More on Clue

Keep looking

Other head to heads